Program
QLC5508
A development code. Also written as “QLC5508 (Investigational Product / Formulation T)” and “QLC5508 (Reference Product / Formulation R)”.
Its studies are mostly in Small Cell Lung Carcinoma · Carcinoma, Neuroendocrine · Prostatic Neoplasms · Esophageal Squamous Cell Carcinoma, led by Qilu Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Qilu Pharmaceutical | 66 open or running | phase 3since Mar 3, 2026 | Sep 28, 2025 | Dec 5, 2026phase 1 · NCT07620041 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 28, 2025First study: phase 2 study in Advanced Solid TumorFirst studyNCT07256782 · 444 planned · China
- Mar 3, 2026Phase 3 study in Esophageal Squamous Cell CarcinomaPhase 3 reachedNCT07463573 · 466 planned · China
- May 12, 2026Phase 1 study in Refractory or Relapsed Solid TumorsNCT07620041 · 48 planned · China
- Jun 2, 2026Phase 3 study in Prostatic NeoplasmsNCT07632690 · 700 planned
- Aug 30, 2026Phase 3 study in Small Cell Lung CarcinomaNCT07802821 · 556 planned · China
- Oct 18, 2026Phase 3 study in Extrapulmonary Neuroendocrine CarcinomaNCT07894211 · 270 planned
Ahead
- Dec 5, 2026Primary completion: phase 1 study in Refractory or Relapsed Solid TumorsNCT07620041
- Jun 5, 2028Primary completion: phase 3 study in Esophageal Squamous Cell CarcinomaNCT07463573
- Jun 20, 2028Primary completion: phase 3 study in Prostatic NeoplasmsNCT07632690
- Mar 15, 2029Primary completion: phase 3 study in Small Cell Lung CarcinomaNCT07802821
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07894211Extrapulmonary Neuroendocrine Carcinoma | 3 | Not yet recruiting | Mar 26, 2029 | 270 |
| NCT07802821Small Cell Lung Carcinoma · China | 3 | Recruiting | Mar 15, 2029 | 556 |
| NCT07632690Prostatic Neoplasms | 3 | Not yet recruiting | Jun 20, 2028 | 700 |
| NCT07620041Refractory or Relapsed Solid Tumors · China | 1 | Recruiting | Dec 5, 2026 | 48 |
| NCT07463573Esophageal Squamous Cell Carcinoma · China | 3 | Recruiting | Jun 5, 2028 | 466 |
| NCT07256782Advanced Solid Tumor · China | 2 | Recruiting | Oct 2026 | 444 |
How it is read
Names in the registry
- “QLC5508”, 5 entries
- “QLC5508 (Investigational Product / Formulation T)”, 1 entry
- “QLC5508 (Reference Product / Formulation R)”, 1 entry
Codes read as this program: QLC5508.
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 1 study
- Carcinoma, Neuroendocrine, 1 study
- Prostatic Neoplasms, 1 study
- Esophageal Squamous Cell Carcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.